QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:MDGL

Madrigal Pharmaceuticals Earnings Date, Estimates & History

$111.94
-1.32 (-1.17 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$111.81
Now: $111.94
$114.48
50-Day Range
$113.04
MA: $125.70
$133.70
52-Week Range
$56.82
Now: $111.94
$137.28
Volume94,915 shs
Average Volume164,241 shs
Market Capitalization$1.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.58

Earnings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Information

Madrigal Pharmaceuticals last announced its quarterly earnings results on November 5th, 2020. The biopharmaceutical company reported ($3.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.37) by $0.38. Madrigal Pharmaceuticals has generated ($5.45) earnings per share over the last year. Madrigal Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 24th, 2021 based off prior year's report dates.

Madrigal Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Estimates

2020 EPS Consensus Estimate: ($10.25)
2021 EPS Consensus Estimate: ($14.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20202($1.93)($1.87)($1.90)
Q2 20203($2.47)($2.01)($2.17)
Q3 20204($3.38)($2.17)($2.86)
Q4 20204($3.87)($2.31)($3.32)
Q1 20211($3.53)($3.53)($3.53)
Q2 20211($3.53)($3.53)($3.53)
Q3 20211($3.60)($3.60)($3.60)
Q4 20211($3.76)($3.76)($3.76)

Madrigal Pharmaceuticals (NASDAQ MDGL) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
2/24/2021
(Estimated)
       
11/5/20209/30/2020($3.37)($3.75)($3.75)Listen
8/6/20206/30/2020($2.43)($3.18)($3.18)N/A
5/7/20203/31/2020($1.94)($2.34)($2.34)N/A
2/26/2020Q4 2019($1.67)($1.80)($1.80)N/A
11/6/2019Q3($1.42)($1.39)($1.39)N/A
8/7/2019Q2 2019($1.22)($1.28)($1.28)N/A
5/8/20193/31/2019($1.00)($0.98)($0.98)N/A
2/27/2019Q4 2018($0.75)($0.75)($0.75)N/A
11/6/20189/30/2018($0.53)($0.56)($0.56)N/A
8/7/2018Q2 2018($0.6260)($0.45)($0.45)N/A
5/8/2018Q1 2018($0.7770)($0.45)($0.45)N/A
3/13/2018Q4 2017($0.70)($0.67)($0.67)N/A
11/9/2017Q3 2017($0.7870)($0.68)($0.68)N/A
8/10/2017Q2 2017($0.60)($0.69)($0.69)N/A
5/11/2017Q1 2017($0.87)($0.50)($0.50)N/A
4/3/2017Q4 2016($1.39)($0.67)($0.67)N/A
11/14/2016Q3 2016($1.34)($1.34)N/A
7/20/2016Q2 2016($0.70)($0.70)N/A
5/10/2016Q1 2016($1.75)($1.75)N/A
3/15/2016Q4($0.18)($0.08)($0.08)N/A
11/5/2015Q3($0.16)($0.13)($0.13)N/A
8/6/2015Q215($0.18)($0.15)($0.15)Listen
5/7/2015Q115($0.19)($0.19)($0.19)Listen
3/12/2015Q4($0.19)($0.19)($0.19)$0.13 millionListen
11/6/2014Q3($0.23)($0.19)($0.19)$0.13 millionListen
8/6/2014Q2($0.25)($0.24)($0.24)$480.00 millionListen
5/8/2014Q1($0.28)($0.28)($0.28)Listen
3/11/2014Q4 2013($10.84)($10.84)($10.84)$0.37 millionListen
11/4/2013Q3 2013($11.89)($11.54)($11.54)Listen
8/1/2013Q2 2013($10.49)($11.54)($11.54)Listen
4/30/2013Q1 2013($9.79)($10.49)($10.49)N/A
3/14/2013Q4 2012($9.44)($10.14)($10.14)N/A
11/6/2012Q312($0.24)($0.25)$1.60 millionN/A
8/2/2012Q2 2012($9.44)($8.88)($8.88)N/A
5/3/2012Q1 2012($8.74)($9.44)($9.44)N/A
2/22/2012Q4 2011($9.44)($7.59)($7.59)N/A
11/3/2011Q3 2011($9.79)($10.56)($10.56)N/A
8/4/2011Q2 2011($6.64)($10.35)($10.35)N/A
5/5/2011Q1 2011($9.44)($9.48)($9.48)N/A
3/11/2011Q4 2010($5.24)($7.48)($7.48)N/A
11/4/2010Q3 2010($7.69)($8.88)($8.88)N/A
8/9/2010Q2 2010($8.04)($7.69)($7.69)N/A
5/4/2010Q1 2010($7.34)($8.39)($8.39)N/A
3/11/2010Q4 2009($9.09)($7.24)($7.24)N/A
11/4/2009Q3 2009$61.19$121.82$121.82N/A
8/4/2009Q2 2009($11.89)($8.78)($8.78)N/A
5/7/2009Q1 2009($18.88)($23.01)($21.75)N/A
3/26/2009Q4 2008($28.32)($26.89)($26.89)N/A
11/13/2008Q3 2008($22.38)($27.27)($27.27)N/A
8/7/2008Q2 2008($19.93)($23.53)($23.53)N/A
5/14/2008Q1 2008($19.23)($18.29)($18.29)N/A
3/20/2008Q4 2007($18.18)($16.12)($16.12)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.